Literature DB >> 20484501

Use of a virus-encoded enzymatic marker reveals that a stable fraction of memory B cells expresses latency-associated nuclear antigen throughout chronic gammaherpesvirus infection.

Michael S Nealy1, Carrie B Coleman, Haiyan Li, Scott A Tibbetts.   

Abstract

An integral feature of gammaherpesvirus infections is the ability to establish lifelong latency in B cells. During latency, the viral genome is maintained as an extrachomosomal episome, with stable maintenance in dividing cells mediated by the viral proteins Epstein-Barr nuclear antigen 1 (EBNA-1) for Epstein-Barr virus and latency-associated nuclear antigen (LANA) for Kaposi's sarcoma-associated herpesvirus. It is believed that the expression of episome maintenance proteins is turned off in the predominant long-term latency reservoir of resting memory B cells, suggesting that chronic gammaherpesvirus infection is primarily dormant. However, the kinetics of LANA/EBNA-1 expression in individual B-cell subsets throughout a course of infection has not been examined. The infection of mice with murine gammaherpesvirus 68 (MHV68, gammaHV68) provides a model to determine the specific cellular and molecular events that occur in vivo during lifelong gammaherpesvirus latency. In work described here, we make use of a heterologously expressed enzymatic marker to define the types of B cells that express the LANA homolog (mLANA) during chronic MHV68 infection. Our data demonstrate that mLANA is expressed in a stable fraction of B cells throughout chronic infection, with a prominent peak at 28 days. The expression of mLANA was detected in naïve follicular B cells, germinal-center B cells, and memory B cells throughout infection, with germinal-center and memory B cells accounting for more than 80% of the mLANA-expressing cells during the maintenance phase of latency. These findings suggest that the maintenance phase of latency is an active process that involves the ongoing proliferation or reseeding of latently infected memory B cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484501      PMCID: PMC2897616          DOI: 10.1128/JVI.02572-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters.

Authors:  Matthias Ottinger; Daniel Pliquet; Thomas Christalla; Ronald Frank; James P Stewart; Thomas F Schulz
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

2.  Identification of infected B-cell populations by using a recombinant murine gammaherpesvirus 68 expressing a fluorescent protein.

Authors:  Christopher M Collins; Jeremy M Boss; Samuel H Speck
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

3.  NF-kappaB p50 plays distinct roles in the establishment and control of murine gammaherpesvirus 68 latency.

Authors:  Laurie T Krug; Christopher M Collins; Lisa M Gargano; Samuel H Speck
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

4.  Blimp-1-dependent plasma cell differentiation is required for efficient maintenance of murine gammaherpesvirus latency and antiviral antibody responses.

Authors:  Andrea M Siegel; Udaya Shankari Rangaswamy; Ruth J Napier; Samuel H Speck
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

5.  A replication-defective gammaherpesvirus efficiently establishes long-term latency in macrophages but not in B cells in vivo.

Authors:  Haiyan Li; Kazufumi Ikuta; John W Sixbey; Scott A Tibbetts
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Reduction in RNA levels rather than retardation of translation is responsible for the inhibition of major histocompatibility complex class I antigen presentation by the glutamic acid-rich repeat of herpesvirus saimiri open reading frame 73.

Authors:  Jiayu Gao; Judy M Coulson; Adrian Whitehouse; Neil Blake
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

7.  ORF73-null murine gammaherpesvirus 68 reveals roles for mLANA and p53 in virus replication.

Authors:  J Craig Forrest; Clinton R Paden; Robert D Allen; Julie Collins; Samuel H Speck
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

8.  In vivo imaging of murid herpesvirus-4 infection.

Authors:  Ricardo Milho; Christopher M Smith; Sofia Marques; Marta Alenquer; Janet S May; Laurent Gillet; Miguel Gaspar; Stacey Efstathiou; J Pedro Simas; Philip G Stevenson
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

9.  Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals.

Authors:  Micah J Benson; Raul Elgueta; William Schpero; Michael Molloy; Weijun Zhang; Edward Usherwood; Randolph J Noelle
Journal:  J Exp Med       Date:  2009-08-24       Impact factor: 14.307

10.  Termination of NF-kappaB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase.

Authors:  Lénia Rodrigues; Josina Filipe; Mark P Seldon; Lidia Fonseca; Josef Anrather; Miguel P Soares; J Pedro Simas
Journal:  EMBO J       Date:  2009-03-26       Impact factor: 11.598

View more
  27 in total

1.  Immature and transitional B cells are latency reservoirs for a gammaherpesvirus.

Authors:  Carrie B Coleman; Michael S Nealy; Scott A Tibbetts
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Tiled microarray identification of novel viral transcript structures and distinct transcriptional profiles during two modes of productive murine gammaherpesvirus 68 infection.

Authors:  Benson Yee Hin Cheng; Jizu Zhi; Alexis Santana; Sohail Khan; Eduardo Salinas; J Craig Forrest; Yueting Zheng; Shirin Jaggi; Janet Leatherwood; Laurie T Krug
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Critical roles of chemokine receptor CCR10 in regulating memory IgA responses in intestines.

Authors:  Shaomin Hu; KangKang Yang; Jie Yang; Ming Li; Na Xiong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

4.  Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis.

Authors:  Brian F Niemeyer; Lauren M Oko; Eva M Medina; Darby G Oldenburg; Douglas W White; Carlyne D Cool; Eric T Clambey; Linda F van Dyk
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 5.  Gammaherpesviruses and B Cells: A Relationship That Lasts a Lifetime.

Authors:  Kaitlin E Johnson; Vera L Tarakanova
Journal:  Viral Immunol       Date:  2020-01-08       Impact factor: 2.257

6.  Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency In Vivo.

Authors:  Arundhati Gupta; Shana M Owens; Darby G Oldenburg; Douglas W White; J Craig Forrest
Journal:  J Virol       Date:  2022-06-01       Impact factor: 6.549

7.  LXR Alpha Restricts Gammaherpesvirus Reactivation from Latently Infected Peritoneal Cells.

Authors:  P T Lange; C N Jondle; E J Darrah; K E Johnson; V L Tarakanova
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

8.  Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.

Authors:  Semra Kati; Edward H Tsao; Thomas Günther; Magdalena Weidner-Glunde; Thomas Rothämel; Adam Grundhoff; Paul Kellam; Thomas F Schulz
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

9.  Deletion of Murine Gammaherpesvirus Gene M2 in Activation-Induced Cytidine Deaminase-Expressing B Cells Impairs Host Colonization and Viral Reactivation.

Authors:  Shana M Owens; Darby G Oldenburg; Douglas W White; J Craig Forrest
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

10.  The absence of M1 leads to increased establishment of murine gammaherpesvirus 68 latency in IgD-negative B cells.

Authors:  Laurie T Krug; Andrew G Evans; Lisa M Gargano; Clinton R Paden; Samuel H Speck
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.